

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Satoshi HIHARA et al.
Title: INTERACTION INHIBITORS, METHOD OF DETECTING INTERACTION INHIBITOR AND KIT FOR DETECTING INTERACTION INHIBITOR
Appl. No.: Unassigned
Filing Date: 02/17/2006
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

Documents A1-A3 and A5-A8 listed on the attached PTO/SB/08 were cited as being relevant during a search of the corresponding International application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date February 17, 2006

By  _____

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5426
Facsimile: (202) 672-5399

Glenn Law
Attorney for Applicant
Registration No. 34,371

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: February 17, 2006 <i>(use as many sheets as necessary)</i>			Complete if Known Application Number: Unassigned Filing Date: 02/17/2006 First Named Inventor: Satoshi HIHARA Group Art Unit: Unassigned Examiner Name: Unassigned Attorney Docket Number: 028567-0145		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	01/31051	A2	ISIS PHARMACEUTICALS, INC.	05-03-2001		
	A2	WO	03/004612	A2	YALE UNIVERSITY	01-16-2003		
	A3	WO	03/054228	A2	AXXIMA PHARMACEUTICALS AG	07-03-2003		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	I. Horak, "Immunodeficiency in IL-2-Knockout Mice," Clinical Immunology and Immunopathology, Vol. 76, No. 3, September 1995, page S172-S173.	
	A5	M. D. Cunningham et al., "An intracellular targeted NLS peptide inhibitor of karyopherin α :NF- κ B interactions," Biochemical and Biophysical Research Communications, Vol. 300, No. 2, Jan. 10, 2003, pages 403-407.	
	A6	C. W. Arendt et al., "Protein kinase C- θ signaling from the center of the T-cell synapse," Curr. Opin. Immunol., Vol. 14, No. 3, 2002, pages 323-330.	
	A7	N. Coudronniere et al., "NF- κ B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C- θ ," Proc. Natl. Acad. Sci., Vol. 97, No. 7, (2000), pages 3394-3399.	
	A8	N. Abboushi et al., "Ceramide Inhibits IL-2 Production by Preventing Protein Kinase C-Dependent NF- κ B Activation: Possible Role in Protein Kinase C- θ Regulation," J. Immunol., Vol. 173, No. 5, 1 Sept. 2004, pages 3193-3200.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.